ORMP catalyst calendar

ORAMED PHARMACEUTICALS INC.

Upcoming catalysts
1
Cash runway
16.6 months
Cash & investments
$16M
Phase 3 programs
3

ORAMED PHARMACEUTICALS INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. on April 25, 2027. There is 1 upcoming event on record.

Cash runway is approximately 16.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 12 concluded trials, 83% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
April 25, 2027 A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. Trial Milestone Phase 3

Track ORMP alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open ORMP in the tracker

Recent history

DateEventTypePhase
June 30, 2026 8-K filed: Other event Filing —
March 31, 2026 8-K filed: Material agreement, Acquisition completed Corporate —
February 20, 2026 8-K filed: Material agreement Corporate —
January 14, 2026 8-K filed: Material agreement, Other event Corporate —
January 7, 2026 8-K filed: Other event Filing —
December 31, 2025 8-K filed: Other event Filing —
December 31, 2025 8-K filed: Leadership change Corporate —
November 17, 2025 8-K filed: Material agreement Corporate —
November 17, 2025 Quarterly results filed (8-K) Earnings —
October 24, 2025 Quarterly results filed (8-K) Earnings —
October 6, 2025 8-K filed: Other event Filing —
August 21, 2025 8-K filed: Leadership change Corporate —
July 23, 2025 8-K filed: Material agreement, Other event Corporate —
May 21, 2025 8-K filed: Other event Filing —
April 28, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
January 13, 2023 A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus Trial Milestone Phase 3
January 13, 2023 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus Trial Milestone Phase 3
July 1, 2022 A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH) Trial Milestone Phase 2
June 27, 2022 A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH) Trial Milestone Phase 2
June 7, 2022 A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus Trial Milestone Phase 2
March 1, 2020 A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Trial Milestone Phase 2
February 6, 2020 A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes Trial Milestone Phase 2
October 21, 2019 A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus Trial Milestone Phase 2
February 24, 2017 A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.